Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes (ENTICHIR)

Tokyo University

Status and phase

Completed

Phase 4

Conditions

Intraocular Pressure

Hyperemia

Treatments

Drug: dicrofenac and travoprost

Study type

Interventional

Funder types

Other

Identifiers

CS-097

Details and patient eligibility

About

PG-analogues induce hyperemia as one of side effects in addition to IOP reduction.

IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified.

Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs.

Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.

Enrollment

40 patients

Sex

All

Ages

20 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

normal healthy eye
not applicable for IOP level
not wearing contact lenses
not applicable for the presence of the ocular surface diseases in case the treatment was not needed

Exclusion criteria

the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection
the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months
the eyes with difficulty for the measurement of IOP with the applanation tonometer
the subjects with the allergy for PG-analogues or benzalkonium chloride
the subjects using the eyedrops excluding those in this study
the subjects treated with oral carbonic anhydrase inhibitor
the subject with Sjogren syndrome
the subjects who can not drop periodically
the subjects with the advanced glaucoma or the terminal stage of glaucoma
the subjects with the severe ocular complications